Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021.

Reich, Adam; Reed, Catherine; Schuster, Christopher; Robert, Camille; Treuer, Tamas; Lubrano, Ennio

Reich, Adam; Reed, Catherine; Schuster, Christopher; Robert, Camille; Treuer, Tamas; Lubrano, Ennio.

Affiliation

Reich A; Department of Dermatology, University of Rzeszów, Rzeszów, Poland.
Reed C; Eli Lilly and Company Limited, Bracknell, UK.
Schuster C; Eli Lilly and Company, Vienna, Austria.
Robert C; Lilly France, Neuilly Sur Seine, France.
Treuer T; Lilly Hungária Kft, Budapest, Hungary.
Lubrano E; Internal Medicine and Rheumatology Unit, University of Molise, Campobasso, Italy.

J Dermatolog Treat ; 34(1): 2160196, 2023 Dec.

Article in En | MEDLINE | ID: mdl-36629859

Subject(s)

Arthritis, Psoriatic; Biological Products; Psoriasis; Humans; Arthritis, Psoriatic/drug therapy; Psoriasis/drug therapy; Psoriasis/chemically induced; Antibodies, Monoclonal, Humanized/adverse effects; Biological Products/therapeutic use

Key words

Ixekizumab; psoriasis; psoriatic arthritis; real-world evidence; structured review

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Products / Arthritis, Psoriatic Limits: Humans Language: En Journal: J Dermatolog Treat Journal subject: DERMATOLOGIA Year: 2023 Type: Article Affiliation country: Poland

Fulltext

XML

PubMed Links

Search on Google